FASN and glomerulosclerosis: miR-544 can directly target the mRNA of FASN, and subsequently inhibit glomerulosclerosis and inflammation, thereby alleviating diabetic kidney injury [102], suggesting that FASN is involved in the pathogenesis of DN and that targeting FASN could be a potential approach to treat DN.